



Annual and Financial Report 2017





This publication received funding under an operating grant from the European Union's Health Programme (2014–2020). The content of this publication represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.



Alzheimer Europe Annual and Financial Report 2017

Contents

Annual report	3
Preface	3
Executive summary	5
Introduction	8
AE core activities	9
Objective 1: Providing a voice to people with dementia and their carers	9
Objective 2: Making dementia a European priority	10
Objective 3: Promoting a rights-based approach to dementia	11
Objective 4: Supporting dementia research	12
Objective 5: Strengthening the European dementia movement	14
Other activities and projects	16
Involvement in EU projects	16
Support of European research activities	20
Corporate affairs	21
Annex 1: Meetings attended by AE representatives	24
Meetings organised by Alzheimer Europe in the framework of the 2017 Operating Grant	24
Meetings attended by AE representatives in the framework of the 2017 Operating Grant	24
Other meetings organised by AE or attended by AE representatives in 2017	25
Alzheimer Europe's Board and staff	28
Financial report	29
Report of the réviseur d'entreprises agréé	29
Balance sheet profit and loss account	33
Breakdown of income	35
Our sponsors and supporters	38

Preface



As the Chairperson of Alzheimer Europe, I am very pleased to introduce this year's Annual Report highlighting Alzheimer Europe's activities in 2017. As in previous years, our core activities were funded by the EU health programme, in the form of an operating grant from the European Commission. Alzheimer Europe and its member organisations are very grateful for this ongoing support to improve the lives of people with dementia along with their families and carers.

In 2017, people with dementia were involved in all aspects of AE's work. The European Working Group of People with Dementia (EWGPWD) met on a regular basis to develop and carry out activities such as participating in European research projects and speaking at international conferences. The group also organised a very popular symposium at the 27th Alzheimer Europe Conference and several members participated in the plenary sessions. In December the EWGPWD participated in the 4th European Parliament of Persons with Disabilities where co-chair Chris Roberts gave a speech. In addition, the Chairperson of the EWGPWD participated in all 2017 AE Board meetings as ex-facto members with full voting rights.

It is extremely encouraging to see the adoption of the WHO Global Action plan on the public Health Response to Dementia and on a national level, Alzheimer Europe welcomed the launch of the third national dementia strategy in Scotland (United Kingdom). During the year, there were also ongoing efforts to develop a national strategy for Wales and Sweden and Portugal both announced that work would begin on the development of a dementia strategy. This is a clear and welcome indicator of increased awareness of dementia in individual countries, but also on a Global and European level.

In 2017, Malta took over the six month EU Presidency from the Netherlands and maintained dementia as a priority, with an emphasis on the Promotion of the Rights of People with Dementia which was the theme of the meeting of the Government Group of Experts on Dementia Malta hosted during the Presidency. We are delighted that Helen Rochford-Brennan, chair of the EWGPWD was invited and gave a speech on the rights of people with dementia.

In the European Parliament, the European Alzheimer's Alliance (EAA) now has 127 MEPs from 28 countries and it

remains one of the Parliament's biggest interest groups. In 2017, members of the Alliance provided articles for the Dementia in Europe magazine and hosted or attended our two lunch debates in Brussels. On 27 June, MEP Deirdre Clune (Ireland) hosted the debate focusing on treatment of Alzheimer's dementia. On 5 December, the debate co-hosted by MEPs Heinz K. Becker and Olga Sehnalová focused on improving the diagnosis of Alzheimer's disease thanks to European research collaboration.

In 2017, AE published the "European Dementia Monitor – Comparing and Benchmarking national dementia strategies and policies". This report highlighted the existing inequalities in access to dementia care and treatment across Europe. The report assessed which countries provide the most dementia-friendly policies and guarantee the best support and treatment of people with dementia and their carers. During the year, AE also produced its Dementia in Europe Yearbook, which focuses on standards for residential care facilities in Europe and a discussion paper on Dementia as a disability – Implications for ethics policy and practice.

Thanks to an educational grant by Roche, Alzheimer Europe carried out a survey of 1,407 carers to assess their experiences of a diagnosis in the Czech Republic, Finland, Italy, the Netherlands and the United Kingdom (Scotland) and launched the top line results at its Annual Conference.

In 2017, our European Dementia Observatory continued to grow, both in terms of content and audience reach. Alzheimer Europe published two issues of the Dementia in Europe magazine, which featured a variety of articles on policy developments such as interviews with health ministers, the actions of the EU Presidencies and the global dementia initiatives of the WHO. The monthly AE newsletter, which now reaches close



to 7,600 subscribers, published a total of 661 articles. In addition to policy issues, the newsletter reports on the activities of AE's members and the latest developments in dementia research.

All newsletter articles are posted on AE's website, which saw almost 650,000 unique visitors during the year. AE's 27th Annual Conference took place in Berlin, co-hosted by Deutsche Alzheimer Gesellschaft Selbsthilfe Demenz, the German Alzheimer's Association. Our theme, "Care today, cure tomorrow", attracted 742 delegates – including 38 people with dementia – with a programme featuring some 200 speakers and 212 poster presentations. Our Annual General Meeting took place just before the conference and we were pleased to accept NVO Futura, Montenegro as new provisional members of Alzheimer Europe.

We expanded our participation in EU research projects and is now an active partner in AETIONOMY, AMYPAD, EMIF, EPAD, INDUCT, MinD, MOPEAD, NILVAD, PACE, PredictND,

ROADMAP, SMART4MD and SyDAD. These projects provide an additional funding stream and also allow us to stay at the forefront of European dementia research. AE is also participating in DEM 2, the 2nd European Joint Action on Dementia which brings together ministries of health and academics. We also continued our productive cooperation with INTERDEM, a pan-European research network for psychosocial interventions in dementia and signed a memorandum of agreement outlining our future collaboration.

As always, none of these accomplishments would have been possible without the efforts and commitment of our staff members. My heartfelt thanks go to our dedicated team which is headed by Executive Director Jean Georges and includes Kate Boor-Ellis, Vanessa Challinor, Ana Diaz, Dianne Gove, Gwladys Guillory, Stefanie Peulen and Grazia Tomasini. In 2017, we welcomed two new staff members Christopher Bintener and Cindy Birck who joined the project team.

I would also like to thank the corporate sponsors that provided support to our 2017 activities. We very much appreciate the generosity of AbbVie, Axovant, Eisai, Essity, GE Healthcare, GlaxoSmithKline, HammondCare, Hoffmann-LaRoche, Janssen, Lilly, Lundbeck, Microsoft, MSD, Nestlé, Novartis, Nutricia, Otsuka, Pfizer and Wi-Care.

Let me also thank my fellow Board members for all their helpful advice and support throughout the year, as well as all the representatives from our national member associations and the external experts who provided truly important contributions to our activities and projects. The quality of the Alzheimer Europe work and reports is in no small measure due to their fantastic help and input.

In 2018, I hope that we will be able to build on this collaboration with our national member organisations, external experts and corporate sponsors and look forward to another productive year.

Iva Holmerová
Chairperson of Alzheimer Europe

Executive summary

In 2017, Alzheimer Europe:

- Provided a voice to people with dementia and
 - organised four meetings of the European Working Group of People with Dementia (EWGPWD) with one meeting coinciding with AE's Annual Conference and one with a lunch debate in the European Parliament
 - involved the EWGPWD in the organisation of the Annual Conference by including representatives in the Programme Committee to help with the selection of abstracts, by inviting them to deliver one keynote presentation and by asking them to organise a special symposium on the experience of living with dementia
 - involved the EWGPWD in various EU projects where AE is asked to provide the views of people with dementia
 - involved the Chairperson of the European Working Group of People with Dementia as a full voting member at AE Board meetings
 - ensured people with dementia and carers were represented in all AE projects and working groups
 - collaborated with the Alzheimer Europe Foundation which provided bursaries for people with dementia attending the AE Conference and awards for the best conference posters
- Made dementia a European priority and
 - coordinated with the Maltese EU Presidency and attended a meeting of EU government experts on dementia in Malta
 - continued its work with the European Alzheimer's Alliance and counted 125 Members of the European Parliament from 27 EU countries as members of the alliance by the end of the year
 - involved members of the European Alzheimer's Alliance in the organisation of two lunch debates in the European Parliament
 - organised three company round tables bringing together the AE Board, representatives of corporate sponsors and AE member organisations to discuss the progress of the organisation's different corporate projects,
 - published two editions of the Dementia in Europe magazine,
 - continued working with the new Joint Action on Dementia coordinated by the Scottish Government and contributed to the four priority actions of timely diagnosis and post-diagnostic support, crisis management and care coordination, quality of residential care and dementia-friendly communities
- Promoted a rights-based approach to dementia and
 - identified the ethical implications of recognising dementia as a disability as the priority of the work of its European Dementia Ethics Network
- organised two face-to-face meetings of the public affairs committee for an exchange on EU and national policy developments and campaigns
- played an active role as a member of the European Patients' Forum and supported the development of positions and statements from the broader patient and carer community in response to EU policy developments
- collaborated with Alzheimer's Disease International on its campaign to make dementia a priority at WHO, OECD, G7 and G20 level and welcomed the adoption of the WHO Global Action Plan on Dementia as a result of this campaign,
- played an active role on the Patients' and Consumers' Working Party of the European Medicines Agency



Members of the European Working Group of People with Dementia participate in 4th European Parliament



Alzheimer Europe and INTERDEM signing memorandum of understanding

- set up a working group comprised of ethicists, clinicians, researchers and people with dementia and carers to meet twice in 2017 to discuss the ethical implications of recognising dementia as a disability
- published a report with the results of the literature review and recommendations on the recognition of dementia as a disability
- joined the European Disability Forum to collaborate with other European organisations on the development of a European disability strategy and the implementation of the UN Convention on the Rights of Persons with Disabilities (UNCRPD)
- participated with the EWGPWD in the 4th European Parliament of Persons with Disabilities.
- continued working with the Council of Europe and contribute to ongoing discussions on legal capacity, guardianship systems and bioethics
- Supported dementia research and
 - continued with the development of its European Dementia Observatory by proactively identifying relevant policy and research developments and communicating them to its member organisations and wider community
 - involved its Expert Advisory Panel in commenting on and providing context to breaking research stories
 - published a Research Digest at the end of the year highlighting the key scientific developments in different scientific areas
 - organised the 27th AE Conference in Berlin, Germany from 2 to 4 October under the motto “Care today, cure tomorrow” in collaboration with Deutsche Alzheimer Gesellschaft, the German Alzheimer’s association
- involved its Expert Advisory Panel in the selection of breaking research topics and the selection of abstracts
- attracted 742 participants from 41 countries to the conference
- improved the collaboration with the INTERDEM network and signed a memorandum of understanding outlining the areas for future collaboration
- collaborated more closely with the European Alzheimer’s Disease Consortium (EADC) and participated in EADC meetings
- issued a call for abstracts to be submitted under the following four key areas: research, policies and strategies, innovative care and dementia-friendly society
- evaluated participants’ satisfaction with the conference programme and practical organisation and 96.43% of surveyed participants confirmed they would recommend the conference to their colleagues
- identified care standards in residential care as the focus of its 2017 Yearbook, developed national reports describing the situation in different European countries, produced a comparative report with the findings and identified a number of best practices in this field
- continued to partner with Newsweaver for the sending of its e-mail newsletter and expanded the list of people receiving the newsletter to 7,726
- promoted its website and attracted 651,622 unique visitors to its website

- ensured social media were a full part of the organisation's communication activities and ended the year with 7,500 Twitter followers and 7,175 Facebook likes
- continued to engage with the Innovative Medicines Initiative, the Joint Programme Neurodegenerative Diseases Research (JPND), Horizon2020 and the European Innovation Partnership on Active and Healthy Ageing to identify additional opportunities to participate in EU projects
- continued its active involvement in a number of EU funded projects by representing the views of people with dementia and their carers in the research consortium, by contributing to the ethical discussions and by supporting the communication and dissemination activities towards a non-scientific audience:
 - AETIONOMY (development of an aetiology-based taxonomy of dementias)
 - AMYPAD (Amyloid imaging to prevent Alzheimer's disease)
 - EMIF (European Medical Information Framework)
 - EPAD (European Prevention of Alzheimer's Dementia)
 - MOPEAD (Models of Patient engagement in Alzheimer's disease)
 - PACE (effectiveness of palliative care for elderly people in long term care facilities in Europe)
 - PredictND (objective and systematic ICT-based approach for the diagnosis of neurodegenerative diseases)
 - SMART4MD (Support, Monitoring And Reminder Technology for Mild Dementia)
 - ROADMAP (Real world outcomes across the AD spectrum for better care)
- collaborated with the following EU projects
 - INDUCT (Interdisciplinary Network for Dementia Utilising Current Technology)
 - MinD (Designing for People with Dementia)
 - SYDAD (Synaptic Dysfunction in Alzheimer's Disease)
- ended its collaboration with the project
 - SMART4MD (Support, Monitoring And Reminder Technology for Mild Dementia)
- developed a number of projects funded thanks to the support of its corporate sponsors and partners
- made available on its website dementia-friendly information on phase III clinical trials conducted in Europe
- carried out a survey of 1,409 carers' experiences of a diagnosis in the Czech Republic, Finland, Italy, the Netherlands and the United Kingdom (Scotland) thanks to an educational grant by Roche and launched the top line results at its Annual Conference
- Strengthened the European dementia movement and
 - updated its member organisations on relevant EU policy developments and involved them in the development of policy positions through AE's public affairs working group
 - organised its Alzheimer's Association Academy in December 2017 and develop a programme based on the subjects and issues identified by its members
 - financially supported the attendance of representatives from national organisations at the Alzheimer's Association Academy and AE's public affairs meetings
 - organised quarterly meetings of the AE Board to monitor the association's financial situation and the implementation of its work plan
- carried out the different activities financed under the framework agreement (2015–2017) and the 2017 operating grant provided by the health programme of the European Union
- continued its collaboration with Commission services for the development of a new four-year framework agreement (2018–2021)

Introduction

The Strategic Plan of Alzheimer Europe sets out the five main objectives of the organisation and highlights key aims and actions to be undertaken under each objective for the period covered by the plan (2016–2020). This year's Annual Report breaks down the organisation's core activities into these five key strategic objectives and follows the structure of the 2017 Annual Work Plan, which was

adopted at the Annual General Meeting in Copenhagen on 31 December 2016.

In addition, the report highlights the activities undertaken by Alzheimer Europe in support of EU projects it partnered with and presents those activities it carried out thanks to the support of its corporate sponsors.



Alzheimer Europe

AE core activities

In 2017, Alzheimer Europe received the support of the European Commission. The following core activities of the organisation were funded thanks to an operating grant to Alzheimer Europe in the framework of the Public Health Programme.

Objective 1: Providing a voice to people with dementia and their carers

The European Working Group of People with Dementia (EWGPWD) was originally set up by AE in 2012, following consultations with its member organisations in which involvement was identified as a key priority for Alzheimer Europe. Members of the working group are nominated by AE's member organisations for two-year terms and AE supports the meeting attendance of one person with dementia from each nominating organisation as well as that of a carer or other supporter.

In 2017, the EWGPWD met four times from 14–15 May 14–15 and 3–5 September in Luxembourg (Luxembourg), on 1 October in Berlin (Germany) and 5–7 December in Brussels (Belgium).



The European Working Group of People with Dementia, Berlin 2017

The Chairperson Helen Rochford-Brennan participated in all AE Board meetings as a full Board member. The Group was consulted and asked to ensure user representation and involvement in all AE activities.

For the 2016–2018 term, Alzheimer Europe was able to involve twelve different people with dementia who were nominated by their national organisations in Bosnia and Herzegovina, the Czech Republic, Finland, Germany, Ireland, Norway, Portugal, Slovenia, Sweden and the United Kingdom (Wales and Scotland). The person nominated by

Finland, had to leave the group in May and a new member from Finland joined the working group in October 2017.

In 2017, the EWGPWD and/or its members contributed towards:

- AE activities (27th AE Conference, Alzheimer's Association Academy, 2017 Yearbook on standards for residential care facilities, report on dementia as a disability, AE Newsletter, clinical trials watch etc.)
- Joint Action: the working group provided feedback on the work carried out by the work packages on dementia-friendly communities, timely diagnosis and residential care
- EU projects in which AE is involved (ROADMAP, PACE)
- Research activities carried out by other organisations (ActifCare, European Medicines Agency, INDUCT, MinD)
- Two peer-reviewed papers on public and patient Involvement and on palliative care, both of which have been published in a scientific peer-reviewed journal
- The following meetings:
 - Chris Roberts and Alv Orheim and Ana Diaz participated in the INDUCT Winter School in Maastricht (Netherlands) on 12 January 2017 and Chris Roberts presented on the experience of dementia.
 - Helga Rohra made a speech at a conference organised by Fondation M@d@ric Alzheimer on 8 March 2017 in Paris (France), aimed at promoting social research and innovation on dementia and cognitive disabilities in France.
 - Helen Rochford-Brennan made a presentation to the European Commission group of governmental experts on dementia on 16 May 2017 in Malta.
 - Idalina Aguiar, Nina Baláčková and Chris Roberts participated in the INDUCT Summer School in Salamanca (Spain) on 25–29 September 2017.
 - Helen Rochford-Brennan addressed delegates participating in the “what if” roundtable on “The right to dignity: Overcoming the stigma, discrimination and inequalities faced by people with Alzheimer's” held in the European Parliament on 28 September 2017.
 - Helen Rochford-Brennan took part in the Expert Advisory Group (EXAG) meeting of the ROADMAP project on 18 October in Barcelona (Spain).
 - All members of the group participated in the Special Symposium “Living well with dementia. We are still here and I am still ... Amela, Helga, Carol and Idalina” at the AE Conference in Berlin (Germany) on 3 October 2017.

- Chris Roberts participated in a PPI event organised by the MinD project on 18 October.
- Helen Rochford-Brennan addressed delegates attending Alzheimer Finland's Memory Conference on 15–16 November 2017.
- All members of the EWGPWD participated in the 4th European Parliament of Persons with Disabilities (EPPD) on 6 December in Brussels (Belgium). Chris, Robert, the Vice Chair of the EWGPWD, was one of the representatives from different disability-related organisations to give a speech at this event.
- Helen Rochford-Brennan was invited to attend and provide a speech at the launch of the WHO Global Dementia Observatory in Geneva (Switzerland) on 11 and 12 December.

Objective 2: Making dementia a European priority

2017 saw a number of key developments at national, European and global level, which Alzheimer Europe was able to contribute to:

During the Maltese Presidency of the European Union, the Presidency and the European Commission coordinated a meeting of the government experts on dementia where Helen Rochford-Brennan was invited to share her experience of receiving a diagnosis of dementia and of living with and advocating on behalf of dementia. The Executive Director of Alzheimer Europe shared the organisation's work on legal capacity and decision making and shared some identified good practices with the attending experts. During the meeting, the troika of Presidencies (Malta, Slovakia and the Netherlands) also signed a declaration calling for continued European action on dementia.

In 2017, Alzheimer Europe was also actively involved in the 2nd Joint Action on Dementia coordinated by the Scottish Government and participated in the Programme Board and the Evaluation and Dissemination Groups. Alzheimer Europe and its European Working Group of People with Dementia also contributed to three of the four policy priority areas on timely diagnosis and post-diagnostic support, care coordination and crisis management and quality of residential care. The Joint Action's work on timely diagnosis and on dementia-friendly communities was presented at the organisation's Annual Conference in Berlin.

On a global level, the World Health Organisation (WHO) further developed its activities on dementia. After a successful campaign coordinated by Alzheimer's Disease International, the WHO adopted the Global action plan on the public health response to dementia 2017–2025 on 29 May 2017. This plan aims to improve the lives of people with dementia, their carers and families, while decreasing the impact of dementia on communities and countries. It provides a set of actions to realise the vision of a world in which dementia is prevented and people with dementia and their carers receive the care and support they need to live a life with meaning and dignity. On 7 December, the WHO followed up with the official launch of the Global Dementia Observatory, a knowledge hub for dementia, which will provide epidemiological trends and a comparison of national data sources and policies on dementia. Alzheimer Europe was consulted during the development phase of the Global Dementia Observatory and participated as an expert at the launch event.

On a national level, Alzheimer Europe welcomed the launch of the third national dementia strategy in Scotland (United Kingdom). During the year, there were also ongoing efforts to develop a national strategy for Wales and Sweden and Portugal both announced that work would begin on the development of a dementia strategy.

During 2017, the membership of the European Alzheimer's Alliance grew to 128 MEPs from 27 Member States. Françoise Grossetête (France, EPP) continued as Chair of the Alliance. The Vice-Chairs are Nessa Childers (Ireland, S&D), Marisa Matias (Portugal, GUE/NGL), Sirpa Pietikäinen (Finland, EPP), Frédérique Ries (Belgium, ALDE) and Keith Taylor (United Kingdom, Green/EFA).



Sirpa Pietikäinen, MEP (Finland)

Alzheimer Europe gratefully acknowledges the support of all the Members of the European Parliament who were present or represented at the Alzheimer Europe lunch debates, contributed to Alzheimer Europe's Dementia in Europe magazine or supported national member organisations in their campaigns to make dementia a national and European priority.



Sofia Ribeiro, MEP (Portugal)

Heinz K Becker, MEP (Austria)

- Disability-related terms and definitions
- The disability movement
- Different models (or ways of making sense) of disability
- Personhood and dementia
- Human rights and opportunities
- Policy and practice
- Care, support, disability and dementia
- Working towards an inclusive society

As in previous years, Alzheimer Europe was an active member of the European Patients' Forum (EPF) and contributed, alongside other European organisations, to the development of cross-disease positions on EU consultations and legislative proposals. Alzheimer Europe contributed to EPF's Access to Healthcare campaign.

AE worked closely with its member associations and organised two meetings with public affairs representatives to discuss EU policy developments and to have an active exchange on national lobbying and campaigning activities.

Finally, Alzheimer Europe continued its collaboration with the European Medicines Agency (EMA) in 2017 as an accredited patient organisation and as a full member of EMA's Patients' and Consumers' Working Party (PCWP). AE staff participated in PCWP meetings organised during the course of the year and the annual training session for representatives of patients' associations. A member of the EWGPWD, supported by AE staff, was invited to participate in the evaluation of a procedure for Alzheimer's disease.


The discussion paper also includes a set of statements which were developed by the two working groups (the expert ethics working group and the European Working Group of People with Dementia) and adopted by the Board of Alzheimer Europe. These statements are aimed at the general public, governments and policy makers, Alzheimer associations, organisations of or for people with disabilities, and regulatory bodies.

The ethics group was chaired by Dianne Gove from Alzheimer Europe and the members were June Andrews (University of Stirling, United Kingdom), Andrea Capstick (University of Bradford, United Kingdom), Carmel Geoghegan (Alzheimer Society of Ireland, Ireland), Jean Georges (Alzheimer Europe, Luxembourg), Sébastien Libert (INDUCT, Belgium), Grainne McGettrick (Acquired Brain Injury Ireland, Ireland), Helen Rochford-Brennan (European Working Group of People with Dementia, Ireland), Helga Rohra (European Working Group of People with Dementia, Germany), Simo Vehmas (Stockholm University, Sweden) and Toby Williamson (Mental Health Foundation, United Kingdom).

Objective 3: Promoting a rights-based approach to dementia

As in previous operating grants, AE continued to focus on ethical issues in 2017 and this led to the publication a discussion paper entitled "Dementia as a disability? Implications for ethics, policy and practice".

In this report, we focus on the possible implications for ethics, policy and practice of raising awareness about the potential of framing dementia as a disability. More specifically, we reflect on what the impact might be in terms of how society is or should be organised and what this means for people's everyday lives. The paper covers the following issues:




Objective 4: Supporting dementia research

Over the past years, Alzheimer Europe has continuously improved the information it provides to its members and external stakeholders on key developments in the field of dementia.

In 2017, AE published 11 editions of its monthly e-mail newsletter, with July and August being combined. These

e-newsletters contained information on AE's activities and those of its member organisations, updates on projects in which AE is involved, interesting policy initiatives both at national and European level, scientific developments, human interest stories, new resources and publications and, job opportunities, as well as accounts written by people living with dementia. The AE newsletter had 7,726 subscribers at the end of 2017. A total of 661 articles were featured in AE's 2017 monthly e-newsletter (730 in 2016). They can be broken down into categories, as follows:

Graph 1: Number of articles




AE's Expert Advisory Panel, set up in 2015, supported the communication on medical and scientific breakthroughs by providing background comments to some research news. The group consists of 35 experts in various areas of dementia from 18 European countries. In 2017, AE published a research digest consisting of all the scientific articles published in the year's newsletters. The Expert Advisory Panel contributed to this publication, provided

a number of commentaries on breaking scientific stories and also evaluated conference abstracts for the 27th Alzheimer Europe Conference in Berlin, Germany.

In 2017, AE's website saw a significant reduction in visitors which declined from a high of 769,489 in 2016 to 651,122 in 2017.

Graph 2: Number of visitors



The organisation also continued to develop its social media presence, particularly on Facebook and Twitter. AE's Facebook page registered 7,175 "likes" at the end of 2017, an increase from 6,593 likes at the end of 2016. As for Twitter, the association had reached over 7,500 followers at the end of 2017 (5,942 at the end of 2016).

All AE team members who are involved in projects and attend AE events are active Twitter users, tweeting from events where they represent the organisation. The total number of Tweets by AE and its team members in 2016 was 2,730 (3,605 in 2016) and tweet impressions reached 2.19 million (2.57 million in 2016). The table below shows AE's own Twitter account activity in 2017:

Table 1: Twitter statistics

Month	Tweets	Tweet impressions	New followers
January	40	42,300	129
February	47	43,600	135
March	56	46,900	132
April	46	45,100	110
May	84	69,800	207
June	159	112,000	130
July	42	65,400	133
August	47	62,000	101
September	64	89,700	186
October	134	133,000	176
November	42	52,800	118
December	64	95,800	72
Total:	825	858,400	1,629

The 27th Alzheimer Europe Conference (#27AEC) took place from 2–4 October 2017 in Berlin, Germany and was organised together with Deutsche Alzheimer Gesellschaft, the German Alzheimer's association.

The event was organised under the theme of "Care today, cure tomorrow" and was attended by 742 participants from 41 countries, including 38 people with dementia. The programme featured 181 speakers delivering oral presentations and 216 poster presentations.

The opening ceremony had participation from representatives of the German Ministries of Health and for Family Affairs, Senior Citizens, Women and Youth. The four plenary sessions were dedicated to "Living with dementia", "Dementia care in the 21st century", "Improving the diagnosis and management of dementia" and a round table discussion on "Current and future research priorities".



The speakers at the opening ceremony of the 27th Alzheimer Europe Conference in Berlin

In addition to the four plenaries, delegates at #27AEC had the choice of 24 different parallel sessions in English, 4 parallel sessions in German and four special symposia organised by the European Working Group of People with Dementia and the sponsors of the AE Conference. The conference ended with an invitation to attend the 28th Alzheimer Europe Conference (#28AEC) in Barcelona in 2018.

Objective 5: Strengthening the European dementia movement


The organisation and provision of residential care in Europe is heterogeneous, with relevant differences in the type of facilities providing care, the funding mechanisms and the regulatory systems for the implementation and overseeing of the quality of the care and support provided in these care settings. The work carried out by AE in 2017 has provided detailed information about standards for residential care facilities with a particular focus on regulatory requirements and standards that have been developed for or with people with cognitive problems or dementia in mind. More specifically, it provides an overview of the requirements that residential care facilities in Europe must comply with when providing care, for the following areas:

- Physical environment,
- Workforce,
- Provision of care and rights,
- Palliative care,
- Abuse and restraint.

The Yearbook which results from the work in that area includes information from 29 European countries. For Belgium and the United Kingdom (UK) separate information is provided for the different parts of the countries (i.e. Wallonia and Flanders in Belgium, and England, Northern Ireland, Wales and Scotland for the UK). The information was provided by AE members. Other national experts were

contacted in countries where AE has no members or if AE member was not able to provide the relevant information. In total, 73 experts from 29 European countries contributed to the report. In addition, members of the European Working Group of People with Dementia (EWGPWD) and their supporters were invited to share their experiences with and views on each of the topics addressed in the report by providing a short written testimonial.

The 2017 Yearbook shows examples of good practices in these five areas across Europe. However, it also highlights some important oversights on how dementia is currently addressed or neglected in frameworks and standards in Europe. Some of the key issues that still need to be considered at policy level are the formulation of clear and legally binding standards with specific considerations of the needs of residents with dementia, appropriate training for staff, awareness raising and the provision of high-quality accessible information to residents, families and staff about their rights and what they should be able to expect from care.



As in previous years, Alzheimer Europe fully involved its member organisations in its meetings, projects and activities. In 2017, Alzheimer Europe organised three capacity building events on 1 March in Luxembourg (dedicated to campaigning and care standards), on 28 June in Brussels

(dedicated to the Joint Action and Palliative care) and on 5 and 6 December in Brussels (dedicated to dementia research and EU programmes i.e. European Social Fund, European Solidarity Corps and European Social Pillar). (10a. New members, Montenegro NVO FUTURA)

The following issues were identified as potential subjects for Alzheimer Europe's capacity building programme:

- National campaigning activities
- Care standards for care services
- The European Joint Action on Dementia and its work on:
 - Timely diagnosis and post-diagnostic support
 - Care coordination and crisis management
 - Residential care
 - Dementia-friendly communities
- Palliative care in the framework of the PACE project
- The role of biomarkers in the diagnosis of Alzheimer's disease/dementia
- EU research collaborations on timely diagnosis: MOPEAD and AMYPAD projects
- Patient and public involvement in dementia research
- Real-world evidence in dementia research
- The European Regional Development and Social Funds
- The European Solidarity Corps
- The European Social Pillar

The Alzheimer Europe Board met four times (February, June, October and December) during the year and monitored the activities and finances of the organisation in relation to the agreed upon Work Plan and Budget.

The Annual General Meeting of Alzheimer Europe took place on 2 October in the framework of the AE Conference in Berlin. At the meeting, the delegates adopted AE's 2016 Annual and Financial reports and approved the 2018 Work Plan and Budget.

Alzheimer Europe also continued its cooperation with INTERDEM, a pan-European research network for

psychosocial interventions in dementia. Several of them were speakers at the conference and also participated in the selection of topics to be addressed. During the AE Conference in Berlin, Germany, a memorandum of understanding between the two organisations outlining their collaboration.

In 2017, Alzheimer Europe also continued its collaboration with other EU organisations, such as AGE Platform Europe, Eurocarers, the Interest Group on Carers of the European Parliament and the European Parliament Interest Group on Patient Access to Healthcare and participated in the think tank meetings of EFPIA – the European Federation of Pharmaceutical Industries and Associations.

AE also further developed its ties with the European Disability Forum which the organisation had joined as an ordinary member at the end of 2016. In 2017, AE contributed to the EDF campaign on the European Accessibility Act and participated with a delegation of the European Working Group of People with Dementia in the 4th European Parliament of Persons with Disabilities.



Chris Roberts at the 4th European Parliament of Persons with Disabilities



Annual General Meeting held in Berlin

Other activities and projects

Involvement in EU projects

Alzheimer Europe has been a full partner in a number of projects funded by the European research programmes Horizon2020, FP7 and the Innovative Medicines Initiative. In these projects, the organisation typically ensures the views of people with dementia, carers and Alzheimer's associations are reflected, contributes to the discussion of the ethical issues raised by the projects and supports or leads the dissemination activities. In 2017, AE supported the following projects.

AETIONOMY

AETIONOMY is a five-year project that began in February 2014. It aims to identify subgroups of dementia and Parkinson's disease – based on the underlying genetic or molecular causes of the variants – in order to allow tailored therapies. Alzheimer Europe is a partner in work package 4: Ethical and Legal Governance.

The organisation was represented by Dianne Gove, Cindy Birck and Christophe Bintener at a meeting in April in Berlin (Germany), by Dianne at a meeting in Stockholm (Sweden) in October and by Dianne and Cindy at the project meetings in November in Basel (Switzerland). Dianne and Ana Diaz contributed towards the ethics guidance documents developed in work package 4.



AETIONOMY Joint Taxonomy workshop in Barcelona (October 2016)

AMYPAD

The "Amyloid imaging to prevent Alzheimer's disease" project aims to improve the diagnostic workup of patients suspected to have Alzheimer's disease and their management. The consortium is led by Stichting VUmc and GE Healthcare Life Sciences. The partners aim to improve knowledge of the natural history of AD in a pre-symptomatic stage, in order to better select patients for trials.

In addition, they will monitor changes in beta amyloid deposition in the brain, in order to quantify the impact of novel therapies.

Alzheimer Europe is co-leading Work Package 6: Ethics, communication and dissemination. AE was represented by Cindy Birck and Jean Georges, who organised and chaired the bi-weekly teleconference meetings. They also attended the General Assembly meeting in October in Amsterdam. They coordinated the production and the regular maintenance of the communication tools (i.e. website, newsletter, Twitter account, press release, general flyer) and were responsible authors of the initial communication plan and the initial report on dissemination tools. Jean also regularly attended the weekly telephone conferences of the AMYPAD Executive Committee. The AMYPAD project was also presented in more detail by Isadora Lopes-Alves to AE members during the organisation's Alzheimer's Association Academy in December.



AMYPAD General Assembly meeting in Amsterdam (October 2017)

In addition, Dianne Gove was active in the ethics subgroup and contributed to the submission of the Ethics Policy and Guidance Document. She represented AE at the ethics meeting organised in January in Cambridge to discuss ongoing work to provide ethics guidance for both the AMYPAD and EPAD projects.

EMIF

The five year European Medical Information Framework project began in 2013 with the aim of developing a framework for evaluating, enhancing and providing access to human health data across Europe.

Alzheimer Europe is a full partner, representing the interests of people with dementia and their carers and is directly involved in the work packages "Sustainability

and Outreach” and “Programme Management and Dissemination”. IN 2017, Alzheimer Europe supported the general communication activities of the project.



EMIF E-magining the Future of Health Data in Budapest (March 2016)

EPAD

EPAD, the European Prevention of Alzheimer’s dementia initiative is a collaborative research project funded by the Innovative Medicines Initiative to improve the chance of successfully preventing Alzheimer’s dementia and to better understand early aspects of Alzheimer’s disease before dementia develops. Led by the University of Edinburgh, the project will establish a European-wide register of research participants, of which 1,500 will be invited to participate in a trial to test new treatments for the prevention of Alzheimer’s dementia.

Alzheimer Europe is co-leading Work Package 6: Dissemination with the participation of Kate Boor-Ellis, Jean Georges and Cindy Birck in several WP6 meetings throughout the year, including the General Assembly meeting in May. They also regularly disseminated project information via social media on Twitter and Facebook, articles on the EPAD project website and contributed to the quarterly external newsletters and the EPAD press releases. Jean also attended the monthly telephone meetings of the Clinical Development Executive (CDEX).

In addition, Dianne Gove was active in Work Package 8: Ethics and was involved in working group discussions and deliverables. She contributed to setting up the participant panel and co-authored the article “Perspectives on communicating biomarker-based assessments of Alzheimer’s



EPAD General Assembly meeting in Edinburgh (May 2015)

disease to cognitively healthy individuals.” She also gave a presentation at a symposium during the General Assembly in Stockholm in May 2017. The EPAD participant portal was presented at the Alzheimer’s Association Academy in December by Stina Saunders.

MOPEAD

MOPEAD or “Models of Patient Engagement for Alzheimer’s Disease” will provide an effective interface between existing efforts in the field (e.g. EMIF and EPAD), in order to identify and test models of efficient earlier identification of mild AD dementia and prodromal AD.



MOPEAD Project kick-off meeting in Barcelona (December 2016)

Alzheimer Europe was represented by Jean Georges, Dianne Gove, and Christophe Bintener at several meetings throughout the year, including consortium meetings in March and October. Jean and Christophe regularly contribute to the discussions of the Dissemination work package in by-weekly telephone conferences. Christophe Bintener also regularly contributed to raising the profile of the project via social media activity on the MOPEAD Twitter account and contributed articles to the MOPEAD project website.

The project also held a special session during Alzheimer Europe’s 27th Annual Conference in October, was presented at Alzheimer Europe’s Alzheimer Association Academy in December as well as during a Lunch Debate at the European Parliament in December.

Dianne Gove was responsible for producing the ethical guidance document (deliverable D1.3) in collaboration with Richard Milne (as external advisor) from the University of Cambridge, the MOPEAD advisory board and with input from Ana Diaz and Jean Georges from Alzheimer Europe. Dianne also contributed towards discussions and the development of materials linked to the disclosure of test results to participants.

NILVAD

In 2017, Alzheimer Europe continued its collaboration with the NILVAD project, a phase III clinical trial of the drug nilvadipine. Alzheimer Europe is a partner in work package 7 (Dissemination and Communication) and is also involved in a substudy on the experiences of trial participants and their caregivers.

In 2017, Jean Georges attended the final project meeting where the final results of the phase III trial were presented and discussed.



NILVAD General Assembly Meeting in Dublin (May 2016)

PACE

The aim of PACE is to compare the effectiveness of palliative care at the end of life for elderly people with and without dementia in long-term care facilities in Europe. This project is coordinated by the Vrije Universiteit Brussel in Belgium.



PACE General Assembly Meeting in Helsinki (May 2016)

In 2017, Ana Diaz and Dianne Gove attended project meetings in May. Dianne and Ana regularly contributed to the discussions of the Impact/Dissemination work package and the user-led forums, which are organised in collaboration with AGE Platform. In 2017, they organised and facilitated a consultation with AE member associations and a focus group discussion with members of the European Working Group of People with Dementia in collaboration with researchers from the PACE project and representatives from AGE Platform.

In May, Dianne and Ana attended a PACE consortium meeting in Treviso (Italy) where Dianne also recorded a video clip about Alzheimer Europe's involvement in the project.

Kate Boor Ellis also regularly contributed to raising the profile of the project via social media activity on the PACE Twitter account and contributed articles to the PACE project website.

PredictND

The PredictND project is coordinated by VTT Technical Research (Finland) and aims to provide an objective and systematic ICT-based approach for the diagnosis of neurodegenerative diseases.

Jean Georges and Dianne Gove represented Alzheimer Europe at several project meetings throughout the year, including the Management Board and consortium meeting in March



PredictND Project team meeting in Copenhagen (March 2017)

Kate Boor Ellis regularly contributed to raising the profile of the project via social media activity on the PredictND Twitter account. Kate also worked together with project leaders to produce a PredictND supplement for the conference (October 2017) edition of the Dementia in Europe magazine, and contributed articles to the PredictND project website. The PredictND consortium also organised a special symposium entitled "Diagnosis of dementia: an interactive and educational session" during the 27th AE Conference.

ROADMAP

The "Real world outcomes across the Alzheimer's disease spectrum for better care: multi-modal data access platform" project will provide the foundation for an integrated data environment and framework for real-world evidence (RWE) in Alzheimer's disease. This will include the development of consensual key outcome measures and data integration tools for dataset characterisation and outcome classification, as well as guidelines on the handling and interpretation of RWE data.

Alzheimer Europe was represented by Jean Georges, Dianne Gove and Christophe Bintener at several project meetings throughout the year. They contributed to the development of systematic literature reviews on meaningful outcomes and meaningful delay in disease progression of AD.

In September, Dianne Gove, Christopher Bintener and Ana Diaz organised and co-facilitated (together with Mia Nelson and Amanda Ly from the University of Edinburgh) a consultation with the EWGPWD on outcome definitions). In addition to this, AE has been co-leading the work package on Communication and Patient/Healthcare Provider Engagement. This included the development and update of the project website, social media, information materials and articles on the projects' aims, progress and results as well as a quarterly disseminated external newsletter. Jean Georges and Christophe Bintener in collaboration with co-lead Laura Campo from Lilly were responsible for producing:

- the report on the project website (D7.1 Project website)
- the report on the initial communication plan, including project branding and policies (D7.2)
- the report on the initial set of communication tools (D7.3)
- the interim report on dissemination activities and communication strategy update (D7.4)

Further, Christophe presented the projects' communication activities at the General Assembly meetings and liaised with the communication team of the overarching initiative Big Data for Better Outcomes (BD4BO) on behalf of ROADMAP's communication team. This included face to face meetings and monthly telephone conferences where communication plans, tools, activities and materials were discussed.

Jean and Christophe were also involved in drafting a general introduction to the ROADMAP project for a peer-reviewed journal in collaboration with the projects' principal investigators and work package leaders.

Dianne Gove is a member of the ROADMAP ethics working group and the Ethics Advisory Board and contributed towards several telephone conferences and the drafting of deliverables for the ethics work package. In December, Dianne Gove and Ana Diaz organised and co-facilitated (together with Andrew Turner from the University of Oxford and Sébastien Libert, a PhD student carrying out a secondment with Alzheimer Europe) a consultation



ROADMAP General Assembly Meeting in Barcelona (October 2017)

with the EWGPWD on the ethical issues linked to data sharing.

The project also held a special session during Alzheimer Europe's 27th Annual Conference in October and was presented in three presentations at Alzheimer Europe's Alzheimer Association Academy in December.

SMART4MD

The four year SMART4MD project coordinated by Anglia Ruskin University in the UK aims at developing an app called Support, Monitoring and Reminder Technology for Mild Dementia (SMART4MD). The app will be designed to help people with mild dementia adhere to treatment regimens as well as allowing them to share health-related data with their carers and doctors.

Alzheimer Europe was represented by Kate Boor-Ellis at a consortium meeting in September, and by Dianne Gove and Ana Diaz, who participated in regular telephone conferences for the project throughout the year. AE also wrote a press release about the project, disseminated by project partners across six European countries in June 2017. Kate Boor Ellis worked with the project leaders to produce a two page article about the project, which was published in the October edition (issue 25) of the Dementia in Europe magazine.

Due to time and staff constraints, Alzheimer Europe decided to discontinue its involvement in the project in the second half of 2017.



SMART4MD General Assembly Meeting in Malmö (September 2017)



Support of European research activities

In addition to the projects described above, Alzheimer Europe played a minor role and supported a number of other research projects at European level.

INDUCT

INDUCT (Interdisciplinary Network for Dementia Utilising Current Technology) is a four year project under the Marie Skłodowska-Curie Actions Programme. The main aim of INDUCT is to develop a premier quality multi-disciplinary, multi-professional and intersectorial education and training research framework for Europe aimed at improving technology and care for people with dementia, and to use the coherent themes and interrelated Early Stage Researchers ESRs within INDUCT to provide the evidence to show how technology can improve the lives of people with dementia.




INDUCT School in Salamanca (September 2017)

In 2017, several members of the EWGPWD, supported by AE staff, contributed to the INDUCT Winter School (Maastricht, the Netherlands) and the INDUCT Summer School (Salamanca, Spain). Sébastien Libert, one of the INDUCT PhD researchers based at the University College London, did a secondment with Alzheimer Europe during which he contributed towards the ethics work on disability and dementia, and provided support during the quarterly meetings of the EWGPWD.

MinD

MinD (Designing for People with Dementia) is a four-year project under the Marie Skłodowska-Curie Actions Programme. The project partners aim to use the concept of mindful design to investigate innovative design solutions, in order to enable self-empowerment and confidence building of people living with dementia.



MinD Project kick-off meeting in in Brussels (March 2016)

Alzheimer Europe, which is represented by Ana Diaz and Dianne Gove in this project, co-hosted together with the University of Luxembourg a two-week visit of the project partners in Luxembourg in June. During this visit, a consultation with the EWGPWD was held in Luxembourg.

SyDAD

SyDAD (Synaptic Dysfunction in Alzheimer's Disease) is a European Training Network sponsored by Horizon2020 Marie Skłodowska Curie Actions. The research programme supports 15 Early Stage Researchers (ESRs, PhD students) with an interest in the area of Alzheimer's disease and synaptic dysfunction. The project is led by the Department of Neurobiology, Care Sciences and Society at Karolinska Institutet (Sweden).



SyDAD annual meeting in Bonn (May 2017)

Alzheimer Europe is a partner organisation in this project supporting the dissemination activities. Cindy Birk attended the SyDAD annual meeting in May in Bonn on behalf of Alzheimer Europe where she gave a presentation of AE.



Corporate affairs

European Parliament lunch debates

In 2017, Alzheimer Europe organised two successful lunch debates in the European Parliament in Brussels:



Deirdre Clune, MEP (Ireland)

- On 27 June 2017, MEP Deirdre Clune hosted an Alzheimer Europe lunch debate in the European Parliament on the “Current and future treatment for Alzheimer’s disease and other dementias”. Prof. Alexander Kurz, (Technical University of Munich, Germany) highlighted the current pharmacological treatment and non-pharmacological management options.

Prof. Simon Lovestone, (University of Oxford, United Kingdom) gave an update on researchers’ latest understanding of Alzheimer’s disease and Alzheimer’s dementia. Prof. Bengt Winblad (Karolinska Institutet, Sweden) gave an overview of ongoing clinical trials including preventative strategies. Dr Elisabetta Vaudano from the Innovative Medicines Initiative (IMI), presented the public private partnership of the Innovative Medicines Initiative (IMI).



Simon Lovestone and Alexander Kurz at lunch debate on treatment for Alzheimer’s disease

- On 5 December 2017, Alzheimer Europe held a successful lunch debate in the European Parliament co-chaired by MEPs Heinz K. Becker (Austria) and Olga Sehnalová (Czech Republic) which focused on improving the diagnosis of Alzheimer’s disease thanks to European research collaboration. Prof. Philip Scheltens, presented “Diagnosing Alzheimer’s disease and Alzheimer’s dementia: A paradigm shift thanks to biomarkers”. Prof. Pierre Krolak-Salmon presented how the 2nd European Joint Action on Dementia has developed a diagnostic framework which could promote and enhance a timely diagnosis of Alzheimer’s disease and other neurocognitive disorders. Dr Jyrki Lötjönen presented the decision support tool developed within the PredictND project and Dr Elisabetta Vaudano showcased the support provided by the Innovative Medicines Initiative on diagnosis with a focus on the MOPEAD and AMYPAD projects.”.



Panel at Alzheimer Europe lunch debate on treatment for Alzheimer’s disease

Both lunch debates were well-attended, with delegates from the European Parliament and Commission, the pharmaceutical industry and AE member associations.

Dementia in Europe magazine

In 2017, Alzheimer Europe published two issues of the Dementia in Europe magazine. The magazines featured a variety of articles on policy developments, including interviews with the following national and European policy makers:

- Justyne Caruana MP, Maltese Parliamentary Secretary for Rights of Persons with Disability
- Maureen Watt, Scottish Minister for Mental Health
- Marianne Thyssen, European Commissioner for Employment, Skills, Social Affairs, Labour Mobility



The 2017 issues include articles about the Maltese and Slovak EU Presidencies, reports of the World Health Organisation’s dementia activities including the launch of WHO’s Global Action Plan on the Public Health Response to Dementia and the launch of the Global Dementia Observatory and news on national dementia strategies in Scotland and Wales.

Issue 25 also included a supplement on the PredictND Project.

Clinical Trial Watch

Alzheimer Europe’s Clinical Trial Watch aims to gather information on phase III clinical trials being conducted in at least one European country. In 2017, Alzheimer Europe continued to develop and improve its innovative online resource providing up-to-date information on clinical trials investigating drugs for the treatment and prevention of Alzheimer’s and other dementias. Information is provided in an easy-to-understand language and trials

are presented by country and by condition. A dementia-friendly version of each study is available for download as a pdf file on the AE website and all information has been checked by a representative of the European Working Group of People with Dementia for understanding and a company representative for accuracy.

The CTW was officially launched in September 2016 and 16 trials have already been reported via this service. Although some trials were removed in 2017 since they were no longer recruiting participants, 7 new trials were added, resulting in 11 clinical trials reported in the database at the end of the year. From April 2017, AE included a new section on “ongoing studies but not recruiting participants”.

European Dementia Monitor



In 2017, AE published the “European Dementia Monitor – Comparing and Benchmarking national dementia strategies and policies”. This report highlighted the existing inequalities in access to dementia care and treatment across Europe. The report assessed which countries provide the most dementia-friendly policies and guarantee the best support and treatment of people with dementia and their carers.

According to the findings of the European Dementia Monitor, no country excelled in all ten categories surveyed. The report also revealed that there were significant differences between European countries with most of the Western and Northern European countries scoring significantly higher than Eastern and Southern European countries.

Carers' Survey

Thanks to an educational grant from Roche, Alzheimer Europe and its member organisations from the Czech Republic, Finland, Italy, the Netherlands and the United Kingdom (Scotland) collaborated with the University of Bangor to develop and translate a questionnaire targeted at carers to better understand the diagnostic process, experiences of carers and existing barriers.

A total of 1,409 carers, from these five countries, have participated in the study. A press release was disseminated in October and the top line results of the study were launched at the AE Annual Conference in Berlin. The findings of the study will be further disseminated in peer-reviewed journals and through a publication for the general public.

The top line findings of the survey were:

- On average, 47% of carers felt that the diagnosis would have been better earlier (ranging from 36.5% in the Netherlands to 52.1% in Italy)
- Amongst the key identified barriers to earlier diagnosis, carers reported the first professional seen not considering that anything was wrong (33%) or



Bob Woods presenting care survey results at Berlin Conference, Berlin 2017

believing it was not worth pursuing a diagnosis (6.6%) and the refusal of the person with dementia to seek help (37.9%)

- Significant differences exist across European countries as to the percentage of people with dementia being informed about their diagnosis with 59.3% of Italian carers reporting that the person had not been informed about their diagnosis and this percentage falling to 23.2% in the Czech Republic, 8.2% in the Netherlands, 4.4.% in Scotland and 1.1% in Finland.



Irish delegates meeting with Nessa Childers, MEP (Ireland) (first from left)

Annex 1: Meetings attended by AE representatives

Meetings organised by Alzheimer Europe in the framework of the 2017 Operating Grant

Date	Meeting	Venue
27–28 February	AE Board	Luxembourg, Luxembourg
1 March	AE Public Affairs Meeting	Luxembourg, Luxembourg
14–15 March	European Working Group of People with Dementia	Luxembourg, Luxembourg
26 April	Ethics expert meeting on dementia and disability	Amsterdam, Netherlands
26–27 June	AE Board	Brussels, Belgium
28 June	AE Public Affairs Meeting	Brussels, Belgium
3–4 September	European Working Group of People with Dementia	Munsbach, Luxembourg
6 September	Ethics expert meeting on dementia and disability	Luxembourg, Luxembourg
1 October	European Working Group of People with Dementia	Berlin, Germany
2 October	AE Board	Berlin, Germany
2–4 October	AE Conference “Care today, cure tomorrow”	Berlin, Germany
4–5 December	AE Board	Brussels, Belgium
5–7 December	European Working Group of People with Dementia	Brussels, Belgium
6–7 December	Alzheimer’s Association Academy	Brussels, Belgium

Meetings attended by AE representatives in the framework of the 2017 Operating Grant

Date	Meeting	Venue
16–17 March	Joint Action on Dementia – Residential care	Sofia, Bulgaria
24 March	European Commission meeting on European Solidarity Corps	Brussels, Belgium
3–4 April	Conference venue study visit	The Hague, Netherlands
4–5 April	Conference venue study visit	Rotterdam, Netherlands
6 April	Eurodiaconia Meeting	Brussels, Belgium
6 April	Meeting with Lufthansa	Luxembourg, Luxembourg
11 April	Meeting with DG SANTE	Luxembourg, Luxembourg
26 April	Meeting with HC&L Solutions	Luxembourg, Luxembourg
27–28 April	European Alzheimer’s Disease Consortium	Bucharest, Romania
2 May	CHAFEA Infoday	Brussels, Belgium
3 May	Meeting with Info-Zenter Demenz	Luxembourg, Luxembourg
15–16 May	European Commission Government expert group on dementia	St. Julian’s, Malta

Date	Meeting	Venue
19 May	PRIME Workshop of the European Medicines Agency	London, United Kingdom
2 June	Alzheimer Scotland Annual Meeting	Edinburgh, United Kingdom
21 June	Workshop on Public health of Joint Programme for neurodegenerative diseases research (JPND)	Paris, France
3–4 July	Conference field visit	Berlin, Germany
14 July	Alzheimer's Society Workshop "Involving the public and patients in research"	London, United Kingdom
7 September	Programme Board of EU Joint Action on Dementia	Lyon, France
10–14 September	67 th session of the WHO Regional Committee for Europe	Budapest, Hungary
19–20 September	Patients' and Consumers' Working Party of European Medicines Agency	London, United Kingdom
21 September	EU4Health meeting	Brussels, Belgium
27 September	Research & Innovation for Europe workshop "What after 2020?"	Brussels, Belgium
18 October	European Patients' Forum working group on access	Brussels, Belgium
19 October	Eurocarers meeting	Brussels, Belgium
24–25 October	Council of Europe Conference on Oviedo Convention	Strasbourg, France
9 November	HRG event	Luxembourg, Luxembourg
11–15 November	ICCA Conference	Prague, Czech Republic
16 November	Memory Conference	Helsinki, Finland
20–21 November	EU Joint Action on Dementia meeting on diagnosis and post-diagnostic support	Paris, France
21 November	Training session of European Medicines Agency	London, United Kingdom
22 November	Patients' and Consumers' Working Party of European Medicines Agency	London, United Kingdom
27 November	EU Health Policy Platform	Brussels, Belgium
28 November	European Commission meeting with stakeholder organisations receiving operating grants	Brussels, Belgium
28 November	MEP Interest Group on Access to Healthcare	Brussels, Belgium
6 December	4 th European Parliament of Persons with Disabilities	Brussels, Belgium
11 December	EU4Health meeting	Brussels, Belgium

Other meetings organised by AE or attended by AE representatives in 2017

Date	Meeting	Venue
6 January	Meeting with Roche	Luxembourg, Luxembourg
9–10 January	EPAD/AMYPAD meeting on ethics	Cambridge, United Kingdom
10 January	ROADMAP communications meeting	Brussels, Belgium
12 January	INDUCT School	Maastricht, Netherlands
17 January	ROADMAP outcome measures meeting	Edinburgh, United Kingdom
18 January	Value of Treatment meeting of European Brain Council	Brussels, Belgium
24 January	ROADMAP Steering Committee	Amsterdam, Netherlands
26 January	Meeting with MSD	Brussels, Belgium
27 January	Meeting with European Patients' Forum	Brussels, Belgium

Date	Meeting	Venue
1 February	NILVAD Steering Committee	London, United Kingdom
7–11 February	CONVENE Forum	Vilnius, Lithuania
13–14 February	EPAD communications meeting	Basel, Switzerland
21–22 February	EFGCP Conference	Brussels, Belgium
22–24 February	EMIF-AD General Assembly	Manchester, United Kingdom
28 February	AE Company Round Table	Luxembourg, Luxembourg
1–2 March	AETIONOMY Steering Committee	Esch/Belval, Luxembourg
3 March	EFPIA Think Tank	Brussels, Belgium
6–7 March	PredictND Management and Project Team	Copenhagen, Denmark
13 March	Meeting with European health NGOs	Brussels, Belgium
14 March	PredictND Interim Review	Brussels, Belgium
15–16 March	IMI Meeting “Collaboration in Alzheimer’s disease”	Brussels, Belgium
16–17 March	MOPEAD Consortium	Brussels, Belgium
20–21 March	AETIONOMY Interim review	Brussels, Belgium
23–24 March	ROADMAP General Assembly	Barcelona, Spain
29 March	Meeting with Robert Bosch Stiftung	Munich, Germany
30 March – 1 April	M&I Spring Forum	Paris, France
31 March	ActifCare	Brescia, Italy
20 April	Meeting with Biogen	Luxembourg, Luxembourg
24–25 April	AETIONOMY/PREDISEADS Joint Ethics Meeting	Berlin, Germany
26–26 April	Alzheimer’s Disease International Elected Board and Council	Kyoto, Japan
3–4 May	Dementia Platform UK Conference	London, United Kingdom
8–9 May	PACE Consortium	Treviso, Italy
8–19 May	MinD project meetings	Esch/Belval, Luxembourg
9–10 May	SyDAD Annual Meeting	Bonn, Germany
9–10 May	Alzheimer’s Prevention European Registries workshop	London, United Kingdom
12 May	ROADMAP Research Questions workshop	Amsterdam, Netherlands
15–17 May	EPAD General Assembly	Stockholm, Sweden
22 May	CEO Initiative lunch during 70 th WHO General Assembly	Geneva, Switzerland
25 May	Swiss Federal Office of Health event on Global Action Plan on Dementia	Geneva, Switzerland
10 June	XV Alzheimer’s Meeting of Galician Federation	Santiago de Compostela, Spain
11–13 June	ROADMAP General Assembly	Barcelona, Spain
13 June	Meeting with European Patients’ Forum	Brussels, Belgium
17 June	Generonotoly panel at University of Vechta	Vechta, Germany
19–20 June	HTAi Conference	Rome, Italy
27 June	European Parliament lunch debate “The current and future treatment of Alzheimer’s disease”	Brussels, Belgium
27 June	AE Company round table	Brussels, Belgium
10 July	EPAD TDC Certification visit	Glasgow, United Kingdom

Date	Meeting	Venue
15 July	MOPEAD Consortium	London, United Kingdom
15 July	GAP/EPAD workshop	London, United Kingdom
16–20 July	Alzheimer's Association International Conference	London, United Kingdom
4–5 September	ROADMAP consultation of European Working Group of People with Dementia	Munsbach, Luxembourg
4–6 September	SMART4MD project consortium meeting	Malmö, Sweden
8 September	Care survey meeting	Amsterdam, Netherlands
11 September	Contenance care meeting	Florence, Italy
14–15 September	EPAD Interim Review	Brussels, Belgium
20 September	Meeting with European Patients' Forum	Brussels, Belgium
26 September	Kick-off meeting of Centre of Excellence in Digital Health and Personalised Medicine	Esch/Belval, Luxembourg
28 September	MSD "What If" Roundtable "The right to dignity"	Brussels, Belgium
28 September	European Health Data Network meeting	Amsterdam, Netherlands
2 October	INTERDEM meeting	Berlin, Germany
4–5 October	MOPEAD Consortium meeting	Berlin, Germany
5 October	PredictND Consortium meeting	Berlin, Germany
9 October	AETIONOMY Project meeting	Stockholm, Sweden
10–11 October	AMYPAD General Assembly	Amsterdam, Netherlands
16–17 October	ROADMAP General Assembly	Barcelona, Spain
18–19 October	IMI Stakeholder Forum	Brussels, Belgium
18 October	ROADMAP EXAG	Barcelona, Spain
19–20 October	AAIC Symposium: "Aging and Alzheimer's disease: Opportunities for therapeutic interventions"	Varna, Bulgaria
27 October	EFPIA think tank	Brussels, Belgium
30 October	MOPEAD Ethics working group	Cambridge, United Kingdom
1–4 November	Clinical Trials on Alzheimer's disease (CTAD) Conference	Boston, USA
6 November	ISPOR Annual European Congress	Glasgow, United Kingdom
8 November	EPAD communications meeting	Beerse, Belgium
15 November	BD4BO communications meeting	London, United Kingdom
20 November	EPAD communications meeting	Amsterdam, Netherlands
28 November	GSK Health Advisory Board	London, United Kingdom
29 November	AETIONOMY Steering Committee	Basel, Switzerland
30 November – 1 December	AETIONOMY General Assembly	Basel, Switzerland
5 December	European Parliament lunch debate "Diagnosis of Alzheimer's disease"	Brussels, Belgium
6 December	Company round table	Brussels, Belgium
11–12 December	Human Brain Project seminar	Paris, France
11–12 December	WHO launch of Global Dementia Observatory	Geneva, Switzerland
13–14 December	Workshop "The road to 2025 – Building the ecosystem for Alzheimer's innovation"	Lausanne, Switzerland

Alzheimer Europe's Board and staff

Members of the Alzheimer Europe Board (2016–2018)



Iva Holmerová
Chairperson
(Czech Republic)



Charles Scerri
Vice-Chairperson
(Malta)



Jim Pearson
Honorary Secretary
(UK-Scotland)



*Maria do Rosário
Zincke dos Reis*
Honorary Treasurer
(Portugal)



Helen Rochford-Brennan
Chairperson of EWGPWD
(Ireland)



Stefanie Becker
(Switzerland)



Marie-Odile Desana
(France)



Sabine Henry
(Belgium)



Sabine Jansen
(Germany)



Sirpa Pietikäinen
(Finland)



Jesús Rodrigo
(Spain)



Štefanija Lukič Zlobec
(Slovenia)

Alzheimer Europe staff members



Jean Georges
Executive Director



Christophe Bintener
Project Officer



Cindy Birck
Project Officer



Kate Boor Ellis
**Communications
Officer**



Vanessa Challinor
Policy Officer



Ana Diaz
Project Officer



Gwladys Guillory
**Event and
Conference
Coordinator**



Dianne Gave
**Director for
Projects**



Stefanie Peulen
Finance Officer



Grazia Tomasini
**Administrative
Assistant**

Financial report




ALZHEIMER EUROPE
Association sans but lucratif

R.C.S. Luxembourg F2773

14, rue Dicks
L-1417 LUXEMBOURG

Report of the Réviseur d'entreprises agréé
and
annual accounts as at December 31, 2017



To the Board of Directors of
ALZHEIMER EUROPE
14, rue Dicks
L-1417 LUXEMBOURG

REPORT OF THE REVISEUR D'ENTREPRISES AGREE

Opinion

We have audited the annual accounts of ALZHEIMER EUROPE (the « Association »), which comprise the balance sheet as at December 31, 2017, and profit and loss account for the year then ended, and notes to the annual accounts, including a summary of significant accounting policies.

In our opinion, the accompanying annual accounts *give a true and fair view* of the financial position of the Association as at December 31, 2017, and of the results of its operations for the year then ended in accordance with Luxembourg legal and regulatory requirements relating to the preparation and presentation of the annual accounts.

Basis for opinion

We conducted our audit in accordance with the Law of the 23 July 2016 on the audit profession (Law of 23 July 2016) and with International Standards on Auditing (ISAs) as adopted for Luxembourg by the « Commission de Surveillance du Secteur Financier » (CSSF). Our responsibilities under those Law and standards are further described in the « Responsibilities of « *Reviseur d'Entreprises Agréé* » for the Audit of the annual accounts » section of our report. We are also independent of the Association in accordance with the International Ethics Standards Board For Accountants' Code of Ethics for Professional Accountants (IESBA Code) as adopted for Luxembourg by the CSSF together with the ethical requirements that are relevant to our audit of the annual accounts, and have fulfilled our other ethical responsibilities under those ethical requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.





Responsibilities of the Board of Directors of Those Charged with Governance for the annual accounts

The Board of Directors is responsible for the preparation and fair presentation of these annual accounts in accordance with Luxembourg legal and regulatory requirements relating to the preparation and presentation of the annual accounts, and for such internal control as the Board of Directors determines is necessary to enable the preparation of annual accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts, the Board of Directors is responsible for assessing the Association's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Association or to cease operations, or has no realistic alternative but to do so.

Responsibilities of the « Réviseur d'Entreprises Agréé » for the Audit of the annual accounts

Our objectives are to obtain reasonable assurance about whether the annual accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue a report of « Réviseur d'Entreprises Agréé » that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Law dated 23 July 2016 and with ISAs as adopted for Luxembourg by the CSSF will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts.

As part of an audit in accordance with the Law dated 23 July 2016, and with ISAs as adopted for Luxembourg by the CSSF, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual accounts whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Association's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

 auditeurs associés

- Conclude on the appropriateness of Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Association's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our report of « Réviseur d'Entreprises Agréé » to the related disclosures in the annual accounts or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our report of « Réviseur d'Entreprises Agréé ». However, future events or conditions may cause the Association to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual accounts, including the disclosures, and whether the annual accounts represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Luxembourg, February 26th 2018

For AUDITEURS ASSOCIES, Cabinet de révision agréé
10A, rue Henri M. Schnadt
L-2530 Luxembourg


Philippe SLENDZAK
Partner

Appendix:

- Annual accounts as at December 31st, 2017

ALZHEIMER EUROPEAssociation sans but lucratif
RCS Luxembourg F2773**Balance sheet as of December 31, 2017**

	2017 (Euro)	2016 (Euro)
ASSETS		
Fixed assets		
Other fixed assets	20 782	29 551
Current assets		
Debtors European Commission	177 582	186 847
Other debtors	60 545	53 317
Cash at bank and on deposit	275 500	640 814
	<u>513 627</u>	<u>880 978</u>
Prepayments	50 552	2 560
	<u>584 961</u>	<u>913 088</u>
LIABILITIES		
Capital and reserves		
Results brought forward	239 140	217 561
Result of the year	37 197	21 579
	<u>276 337</u>	<u>239 140</u>
Creditors		
EU Subsidies received on account	72 658	423 438
Tax and social security	24 233	28 838
Payments received on account	50 000	10 000
Trade creditors	86 836	59 657
Other liabilities	27 656	34 615
	<u>261 383</u>	<u>556 548</u>
Deferred income	47 241	117 400
	<u>584 961</u>	<u>913 088</u>

Deferred income represents a part of income received already in 2016 and which will be used in 2018.

As at December 31, 2017, the non-profit organisation had a rental guarantee of KEUR 16 granted to the owner of the offices used by the non-profit organisation.

ALZHEIMER EUROPE

Association sans but lucratif
RCS Luxembourg F2773

Profit and loss account Year ended December 31, 2017

	2017 (Euro)	2016 (Euro)
Other operating income		
EU Subsidy	798 133	594 889
Corporate sponsorship	350 221	535 757
Sponsorship received on account		-117 400
AE Conference registration fees	182 094	184 382
Co-financing in kind	129 513	123 686
Project participation and other subsidies	98 972	101 589
Deferred income	70 160	21 074
Membership fees and contributions	58 067	55 666
Publication sales and royalties	542	7 110
Donations	30	703
Other operating income	11 486	8 576
External charges		
Accommodation expenses	-339 267	-320 162
External experts	-227 766	-215 485
Travel expenses	-105 810	-88 761
Publication and Information material	-89 217	-79 829
Alzheimer Europe Foundation	-62 485	-38 536
Office rent and associated costs	-43 053	-43 378
Communication costs	-43 000	-26 833
Equipment and Leasing	-39 987	-32 207
Recruitment costs	-	-5 604
Office stationery and related costs	-5 793	-5 078
Bank charges	-4 166	-4 013
Membership fees	-3 870	-1 000
Other costs	-48	-49
Staff costs		
Wages and salaries	-598 599	-543 996
Social security costs	-85 138	-76 126
Depreciation	-13 920	-14 221
Interest receivable and similar income	98	827
	37 197	21 579

Breakdown of income

Introduction

In 2017, Alzheimer Europe had an audited income of EUR 1,699,315 of which EUR 1,004,083 (59.09%) were for the organisation's core activities (including the organisation's Annual Conference) and EUR 695,232 (40.91%) were for the organisation's corporate affairs activities and other projects.

Funding of core activities (EUR 1,004,083)

In 2017, the core funding of Alzheimer Europe was composed as follows:

- EUR 445,422 (44.36%) from public funding,
- EUR 182,124 (18.14%) from private individuals,
- EUR 178,367 (17.76%) from member organisations,
- EUR 109,822 (10.94%) from corporate sources,
- EUR 88,250 (8.79%) from foundations and other non-profit organisations,
- EUR 98 (0.01%) from bank interest and similar.

Public funding

In 2017, Alzheimer Europe received EUR 445,422 as an operating grant from the European Commission.

Private individuals

In 2017, AE received EUR 182,124 from individuals which can be broken down as follows:

- EUR 182,094 in conference registrations and
- EUR 30 in donations.

Funding from member organisations

In 2017, the EUR 178,367 funding from member organisations can be broken down as follows:

- EUR 58,067 in membership fees and contributions,
- EUR 120,300 in co-financing from Board members and representatives of member organisations in time donated to the organisation (at EUR 300 per day).

Corporate support

In 2017, Alzheimer Europe received EUR 109,822 from corporate sources as core-funding which can be broken down as follows:

- EUR 35,000 from GlaxoSmithKline as support to the organisation's core activities,
- EUR 20,000 from Hoffmann-La Roche and MSD International GmbH, EUR 10,000 from Lilly, EUR 5,000 from AbbVie, Axovant Sciences and Eisai, 2,500 from HammondCare and 1,250 from Wi-Care to support the AE Conference in Berlin,
- EUR 4,188 from Newsweaver which provided an e-mail facility free of charge,
- EUR 1,884 from Microsoft as discount on software purchases.

Foundations and organisations

The EUR 88,250 which Alzheimer Europe received in 2017 from foundations and other non-profit organisations can be broken down as follows:

- EUR 87,000 as direct support from Fondation Alzheimer, Luxembourg,
- EUR 1,250 from NUI Galway for the AE Conference in Berlin.

Bank interest and similar

In 2017, Alzheimer Europe had an income of EUR 98 from bank interest and similar income.

Funding of project activities (EUR 695,232)

In 2017, Alzheimer Europe received EUR 695,232 for its participation in various EU projects and its corporate affairs activities, of which:

- EUR 352,710 (50.73%) from public sources and
- EUR 320,615 (46.12%) came from corporate sponsors,
- EUR 21,365 (3.07%) from foundations and other non-profit organisations,

- EUR 542 (0.08%) from private individuals.

Public funding

In 2017, Alzheimer Europe received EUR 352,710 as public funding for its participation in various EU projects:

- EUR 91,889 from ROADMAP,
- EUR 52,240 for EPAD,
- EUR 48,798 for PACE,
- EUR 42,338 for AMYPAD,
- EUR 41,282 for PredictND
- EUR 35,077 for MOPEAD
- EUR 23,755 for AETIONOMY,
- EUR 13,548 for Smart4MD,
- EUR 3,784 for EMIF.

Corporate support

The corporate support received by Alzheimer Europe for its activities in 2017 (EUR 320,615) can be broken down as follows:

- Lilly contributed EUR 45,871 as a gold sponsor of AE's corporate programme and as honoraria and travel support,
- Hoffmann-La Roche contributed EUR 40,000 as a gold sponsor of AE's corporate programme,
- Novartis contributed EUR 25,000 for AE's participation in the ROADMAP project,
- Eisai, GE Healthcare, Pfizer and Otsuka contributed EUR 20,000 as silver sponsors of AE's corporate programme,
- Nutricia contributed EUR 15,000 to the organisation's corporate activities,
- Axovant Sciences, Essity and Janssen Pharmaceutica contributed EUR 10,000 as bronze sponsors of AE's corporate programme,
- Merck Sharp & Dohme contributed EUR 5,000 to the organisation's corporate activities,

- Lundbeck and Nestlé contributed EUR 2,500 to participate in the organisation's company round table meetings,
- GSK provided EUR 600 as honoraria for the participation of the Executive Director in GSK meetings,
- Various companies provided EUR 3,984 in travel support,
- EUR 70,160 was income received in account from sponsorship in 2016.

Foundations and organisations

In 2017, Alzheimer Europe received a total of EUR 21,365 from other organisations and foundations, including EUR 5,597 from Nottinghamshire Healthcare for the INDUCT project, EUR 3,163 from the University of Wolverhampton for the organisation's participation in the MIND project, EUR 10,642 from various organisations as travel grants and EUR 1,963 for secretarial costs provided to the Alzheimer Europe Foundation.

Private individuals

In 2017, Alzheimer Europe received EUR 542 in publication sales.

Overall funding

The following table lists all sources of income received in 2017.

In line with the policy of the European Medicines Agency on transparency requirements for accredited patients' organisations, this is presented in total amounts as well as in terms of percentages of the overall income of the organisation.

Funding source	Funding received (2017)	As % of AE income (2017)	As % of AE income (2016)
Hoffmann-La Roche	60,000	3.53%	13.89%
Lilly	55,871	3.29%	5.00%
GlaxoSmithKline	35,600	2.09%	2.34%
Novartis	25,000	1.47%	2.64%
Merck	25,000	1.47%	1.32%
Eisai	25,000	1.47%	
Pfizer	20,000	1.18%	1.32%
GE Healthcare	20,000	1.18%	1.32%








































Funding source	Funding received (2017)	As % of AE income (2017)	As % of AE income (2016)
Otsuka	20,000	1.18%	0.74%
Axovant	15,000	0.88%	0.82%
Janssen	10,000	0.59%	0.66%
AbbVie	5,000	0.29%	
Lundbeck	2,500	0.15%	0.74%
Merz			0.66%
Piramal			0.99%
Biogen			0.99%
Firalis – ADDIA			0.23%
Travel provided free of charge	3,141	0.18%	0.17%
Income received on account	70,160	4.13%	1.39%
Deferred income	0	0.00%	-7.74%
Sub-total: Pharmaceutical funding	392,271	23.08%	27.47%
Nutricia	15,000	0.88%	0.99%
Essity (SCA Global Hygiene)	10,000	0.59%	0.66%
Newsweaver	4,188	0.25%	0.28%
HammondCare	2,500	0.15%	
Nestec	2,500	0.15%	0.16%
Microsoft	1,884	0.11%	0.52%
Wi-Care	1,250	0.07%	
Sub-total: Other corporate sources	37,322	2.20%	2.60%
Total: Corporate funding	429,594	25.28%	30.08%
European Commission	798,133	46.97%	39.21%
Bundesamt für Gesundheit Bern			0.04%
Total: Public funding	798,133	46.97%	39.26%
Fondation Alzheimer, Luxembourg	87,000	5.12%	5.74%
Various organisations	11,486	0.68%	0.57%
University of Nottingham	5,596	0.33%	0.14%
University of Wolverhampton – MinD	3,163	0.19%	0.17%
AE Foundation	1,963	0.12%	0.12%
NUI Galway	1,250	0.07%	0.13%
University of Stirling			0.08%
Fondation Médéric Alzheimer			0.04%
Total: Foundations and organisations	110,458	6.50%	6.99%
Individuals (Conference fees, donations, publications)	182,667	10.75%	12.67%
Total: Individuals	182,667	10.75%	12.67%
AE member organisations	178,367	10.50%	10.95%
Total: Member organisations	178,367	10.50%	10.95%
Bank interest and similar	98	0.01%	0.05%
Total: Bank interest and similar	98	0.01%	0.05%
Total Income	1,699,315	100.00%	100.00%

Our sponsors and supporters



Our members are helping people with dementia and their carers in 35 countries

■ Alzheimer Europe Members

	ALBANIA – TIRANA Alzheimer Albania		GREECE – THESSALONIKI Panhellenic Federation of Alzheimer's Disease and Related Disorders		NORWAY – OSLO Nasjonalforeningen Demensforbundet
	AUSTRIA – VIENNA Alzheimer Austria		HUNGARY – BUDAPEST Social Cluster Association		POLAND – WARSAW Polish Alzheimer's Association
	BELGIUM – BRUSSELS Ligue Nationale Alzheimer Liga		ICELAND – REYKJAVIK The Alzheimer's Association of Iceland		PORTUGAL – LISBON Alzheimer Portugal
	BOSNIA & HERZEGOVINA – SARAJEVO Udruženje AiR		IRELAND – DUBLIN The Alzheimer Society of Ireland		ROMANIA – BUCHAREST Societatea Alzheimer
	BULGARIA – SOFIA Alzheimer Bulgaria		ISRAEL – RAMAT GAN EMDA - The Alzheimer's Association of Israel		SLOVAKIA – BRATISLAVA Slovak Alzheimer's Society
	BULGARIA – VARNA Foundation Compassion Alzheimer		ITALY – MILAN Federazione Alzheimer Italia		SLOVENIA – LJUBLJANA Association "Forget-me-not"
	CROATIA – ZAGREB Alzheimer Croatia		ITALY – ROME Alzheimer Uniti Onlus		SPAIN – MADRID Fundación Alzheimer España
	CYPRUS – LARNACA Pancyprian Alzheimer Association		JERSEY – ST HELIER Jersey Alzheimer's Association		SPAIN – PAMPLONA C.E.A.F.A
	CZECH REPUBLIC – PRAGUE Czech Alzheimer's Society		LUXEMBOURG – LUXEMBOURG Association Luxembourg Alzheimer		SWEDEN – LUND Alzheimerföreringen i Sverige
	DENMARK – HELLERUP Alzheimerforeningen		MALTA – MSIDA Malta Dementia Society		SWEDEN – STOCKHOLM Demensförbundet
	FINLAND – HELSINKI Muistiliitto		MONACO – MONTE-CARLO AMPA - Association Monégasque pour la recherche sur la maladie d'Alzheimer		SWITZERLAND – YVERDON-LES-BAINS Association Alzheimer Suisse
	FRANCE – PARIS Association France Alzheimer		MONTENEGRO – PODGORICA NVO Futura		TURKEY – ISTANBUL Alzheimer Vakfi
	GERMANY – BERLIN Deutsche Alzheimer Gesellschaft e.V.		NETHERLANDS – AMERSFOORT Alzheimer Nederland		UNITED KINGDOM – EDINBURGH Alzheimer Scotland
					UNITED KINGDOM – LONDON Alzheimer's Society



Alzheimer Europe • 14, rue Dicks • L-1417 Luxembourg
Tel.: +352 29 79 70 • Fax: +352 29 79 72 • info@alzheimer-europe.org
www.alzheimer-europe.org



www.facebook.com/alzheimer.europe



[@AlzheimerEurope](https://twitter.com/AlzheimerEurope)

ISBN 978-99959-995-3-7